Osteoporosis Subcutaneous Injection +
Abaloparatide is a novel synthetic peptide analog of hPTHrP (human parathyroid hormone-related protein), a naturally occurring bone building hormone. PTHrP, unlike parathyroid hormone, is critical in the formation of the skeleton, is involved in the regulation of bone formation, and is able to rebuild bone with low associated risk of inducing hypercalcemia as a side effect.
In a Phase 2 clinical trial, abaloparatide administered through a subcutaneous injection (Abaloparatide-SC) produced faster and greater bone mineral density increases at the spine and the hip, with substantially less hypercalcemia, than Forteo® (teriparatide).
Abaloparatide-TD Osteoporosis Transdermal Patch +
Abaloparatide-TD is a line extension of Abaloparatide-SC in the form of a convenient, short-wear-time transdermal patch based on 3M's patented Microstructured Transdermal System technology.
Results of a Phase 2 clinical trial showed efficacy, safety, and tolerability of Abaloparatide-TD in the treatment of osteoporosis. At each dose, Abaloparatide-TD demonstrated a statistically significant mean percent increase from baseline in bone mineral density (BMD) as compared to placebo at the lumbar spine and at the hip. These results demonstrated a clear proof-of-concept by achieving a dose dependent increase in BMD.
RAD1901Breast Cancer Brain Metastases Oral +
RAD1901 is a selective estrogen receptor down-regulator/degrader, or SERD, that crosses the blood-brain barrier and is being evaluated for the treatment of breast cancer brain metastases (BCBM). RAD1901 has been shown to bind with good selectivity to the estrogen receptor and to have both estrogen-like and estrogen-antagonistic effects in different tissues. In many cancers, hormones, like estrogen, stimulate tumor growth and a desired therapeutic goal is to block this estrogen-dependent growth while inducing apoptosis of the cancer cells. SERDs are an emerging class of endocrine therapies that directly induce estrogen receptor, or ER, degradation, enabling them to remove the estrogen growth signal in ER-dependent tumors without allowing ligand-independent resistance to develop. There is currently only one SERD, Faslodex (fulvestrant), approved for the treatment of hormone-receptor positive metastatic breast cancer; however, for patients with BCBM, there are no approved targeted therapies that cross the blood-brain barrier. Radius believes there is a significant opportunity for RAD1901 to be the first ER-targeted therapy that crosses the blood-brain barrier to more effectively treat ER-positive BCBM and potentially reduce both intracranial and extracranial BCBM tumors.
RAD1901 Vasomotor Symptoms Oral +
RAD1901 is in development at lower doses as a selective estrogen receptor modulator, or SERM, for the treatment of vasomotor symptoms. In a Phase 2 proof-of-concept study, RAD1901 demonstrated a reduction in frequency and severity of moderate and severe hot flashes.
RAD140 Cachexia / Frailty / Breast Cancer Oral +
RAD140 is a nonsteroidal selective androgen receptor modulator, or SARM, which is an orally active androgen agonist on muscle and bone. In preclinical studies, RAD140 has demonstrated potent anabolic activity on muscle and bone. Because of its high anabolic efficacy, receptor selectivity, potent oral activity, and long duration half-life, RAD140 has clinical potential in a number of indications where the increase in lean muscle mass and/or bone density is beneficial, such as treating the weight loss due to cancer cachexia, muscle frailty and osteoporosis, and breast cancer.